Cargando…

Good Clinical Response to Erlotinib in a Non-Small Cell Lung Cancer Patient Harboring Multiple Brain Metastases and a Double Active Somatic Epidermal Growth Factor Gene Mutation

Recently, 2 small molecule kinase inhibitors (TKIs), targeting epidermal growth factor receptor (EGFR), have proven effective in the treatment of non-small cell lung cancer. However, it is unknown whether the EGFR double activating mutation of L858R in exon 21 and the in-frame deletion in exon 19 is...

Descripción completa

Detalles Bibliográficos
Autores principales: Masago, Katsuhiro, Togashi, Yosuke, Fukudo, Masahide, Terada, Tomohiro, Irisa, Kaoru, Sakamori, Yuichi, Fujita, Shiro, Kim, Young Hak, Mio, Tadashi, Inui, Ken-ichi, Mishima, Michiaki
Formato: Texto
Lenguaje:English
Publicado: S. Karger AG 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2919984/
https://www.ncbi.nlm.nih.gov/pubmed/20740181
http://dx.doi.org/10.1159/000310830
_version_ 1782185226093461504
author Masago, Katsuhiro
Togashi, Yosuke
Fukudo, Masahide
Terada, Tomohiro
Irisa, Kaoru
Sakamori, Yuichi
Fujita, Shiro
Kim, Young Hak
Mio, Tadashi
Inui, Ken-ichi
Mishima, Michiaki
author_facet Masago, Katsuhiro
Togashi, Yosuke
Fukudo, Masahide
Terada, Tomohiro
Irisa, Kaoru
Sakamori, Yuichi
Fujita, Shiro
Kim, Young Hak
Mio, Tadashi
Inui, Ken-ichi
Mishima, Michiaki
author_sort Masago, Katsuhiro
collection PubMed
description Recently, 2 small molecule kinase inhibitors (TKIs), targeting epidermal growth factor receptor (EGFR), have proven effective in the treatment of non-small cell lung cancer. However, it is unknown whether the EGFR double activating mutation of L858R in exon 21 and the in-frame deletion in exon 19 is a predictor of the effectiveness of EGFR-TKIs. We report for the first time a case of non-small cell lung cancer with central nervous system metastases harboring a rare EGFR double activating mutation who showed a good clinical response to erlotinib, regardless of his poor performance status, as swallowing is not possible. Therefore, we suggest that erlotinib may become a therapeutic choice in cases of central nervous system metastases even with poor performance status.
format Text
id pubmed-2919984
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-29199842010-08-25 Good Clinical Response to Erlotinib in a Non-Small Cell Lung Cancer Patient Harboring Multiple Brain Metastases and a Double Active Somatic Epidermal Growth Factor Gene Mutation Masago, Katsuhiro Togashi, Yosuke Fukudo, Masahide Terada, Tomohiro Irisa, Kaoru Sakamori, Yuichi Fujita, Shiro Kim, Young Hak Mio, Tadashi Inui, Ken-ichi Mishima, Michiaki Case Rep Oncol Published: April 2010 Recently, 2 small molecule kinase inhibitors (TKIs), targeting epidermal growth factor receptor (EGFR), have proven effective in the treatment of non-small cell lung cancer. However, it is unknown whether the EGFR double activating mutation of L858R in exon 21 and the in-frame deletion in exon 19 is a predictor of the effectiveness of EGFR-TKIs. We report for the first time a case of non-small cell lung cancer with central nervous system metastases harboring a rare EGFR double activating mutation who showed a good clinical response to erlotinib, regardless of his poor performance status, as swallowing is not possible. Therefore, we suggest that erlotinib may become a therapeutic choice in cases of central nervous system metastases even with poor performance status. S. Karger AG 2010-04-22 /pmc/articles/PMC2919984/ /pubmed/20740181 http://dx.doi.org/10.1159/000310830 Text en Copyright © 2010 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial-No-Derivative-Works License (http://creativecommons.org/licenses/by-nc-nd/3.0/). Users may download, print and share this work on the Internet for noncommercial purposes only, provided the original work is properly cited, and a link to the original work on http://www.karger.com and the terms of this license are included in any shared versions.
spellingShingle Published: April 2010
Masago, Katsuhiro
Togashi, Yosuke
Fukudo, Masahide
Terada, Tomohiro
Irisa, Kaoru
Sakamori, Yuichi
Fujita, Shiro
Kim, Young Hak
Mio, Tadashi
Inui, Ken-ichi
Mishima, Michiaki
Good Clinical Response to Erlotinib in a Non-Small Cell Lung Cancer Patient Harboring Multiple Brain Metastases and a Double Active Somatic Epidermal Growth Factor Gene Mutation
title Good Clinical Response to Erlotinib in a Non-Small Cell Lung Cancer Patient Harboring Multiple Brain Metastases and a Double Active Somatic Epidermal Growth Factor Gene Mutation
title_full Good Clinical Response to Erlotinib in a Non-Small Cell Lung Cancer Patient Harboring Multiple Brain Metastases and a Double Active Somatic Epidermal Growth Factor Gene Mutation
title_fullStr Good Clinical Response to Erlotinib in a Non-Small Cell Lung Cancer Patient Harboring Multiple Brain Metastases and a Double Active Somatic Epidermal Growth Factor Gene Mutation
title_full_unstemmed Good Clinical Response to Erlotinib in a Non-Small Cell Lung Cancer Patient Harboring Multiple Brain Metastases and a Double Active Somatic Epidermal Growth Factor Gene Mutation
title_short Good Clinical Response to Erlotinib in a Non-Small Cell Lung Cancer Patient Harboring Multiple Brain Metastases and a Double Active Somatic Epidermal Growth Factor Gene Mutation
title_sort good clinical response to erlotinib in a non-small cell lung cancer patient harboring multiple brain metastases and a double active somatic epidermal growth factor gene mutation
topic Published: April 2010
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2919984/
https://www.ncbi.nlm.nih.gov/pubmed/20740181
http://dx.doi.org/10.1159/000310830
work_keys_str_mv AT masagokatsuhiro goodclinicalresponsetoerlotinibinanonsmallcelllungcancerpatientharboringmultiplebrainmetastasesandadoubleactivesomaticepidermalgrowthfactorgenemutation
AT togashiyosuke goodclinicalresponsetoerlotinibinanonsmallcelllungcancerpatientharboringmultiplebrainmetastasesandadoubleactivesomaticepidermalgrowthfactorgenemutation
AT fukudomasahide goodclinicalresponsetoerlotinibinanonsmallcelllungcancerpatientharboringmultiplebrainmetastasesandadoubleactivesomaticepidermalgrowthfactorgenemutation
AT teradatomohiro goodclinicalresponsetoerlotinibinanonsmallcelllungcancerpatientharboringmultiplebrainmetastasesandadoubleactivesomaticepidermalgrowthfactorgenemutation
AT irisakaoru goodclinicalresponsetoerlotinibinanonsmallcelllungcancerpatientharboringmultiplebrainmetastasesandadoubleactivesomaticepidermalgrowthfactorgenemutation
AT sakamoriyuichi goodclinicalresponsetoerlotinibinanonsmallcelllungcancerpatientharboringmultiplebrainmetastasesandadoubleactivesomaticepidermalgrowthfactorgenemutation
AT fujitashiro goodclinicalresponsetoerlotinibinanonsmallcelllungcancerpatientharboringmultiplebrainmetastasesandadoubleactivesomaticepidermalgrowthfactorgenemutation
AT kimyounghak goodclinicalresponsetoerlotinibinanonsmallcelllungcancerpatientharboringmultiplebrainmetastasesandadoubleactivesomaticepidermalgrowthfactorgenemutation
AT miotadashi goodclinicalresponsetoerlotinibinanonsmallcelllungcancerpatientharboringmultiplebrainmetastasesandadoubleactivesomaticepidermalgrowthfactorgenemutation
AT inuikenichi goodclinicalresponsetoerlotinibinanonsmallcelllungcancerpatientharboringmultiplebrainmetastasesandadoubleactivesomaticepidermalgrowthfactorgenemutation
AT mishimamichiaki goodclinicalresponsetoerlotinibinanonsmallcelllungcancerpatientharboringmultiplebrainmetastasesandadoubleactivesomaticepidermalgrowthfactorgenemutation